The article written by Øystein Rekdal (CEO) describes Lytix Biopharma`s strategy
to raise response rates to immunotherapy and how our drug candidates are
mobilizing the body`s immune system towards cancer in a unique way.  The article
also explains how the technology was discovered, leading to construction of
molecules with unique anticancer effects that address some major challenges in
current cancer therapy. 

MedNous is a print publication and website that serves as a comprehensive
resource for individuals involved in medical research across Europe. Founded
with the aim of providing insightful and up-to-date information to professionals
within the medical research community, MedNous covers a wide range of topics
related to biomedical science, pharmaceuticals, healthcare policy, and
technological advancements.

MedNous plays a vital role in facilitating knowledge exchange, networking, and
collaboration within the European medical research community, helping to drive
innovation and advancements in healthcare for the benefit of patients worldwide.

For more information, please contact:
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.